Decoding the Genetic Blueprint: Advancing Personalized Medicine in Type 2 Diabetes through Pharmacogenomics

Objective: The escalation of type 2 diabetes (T2D) as a global health crisis necessitates a shift towards personalized medicine to optimize treatment efficacy and minimize adverse drug reactions (ADRs). This review article underscores the significant role of pharmacogenomics in refining T2D management. We explore the influence of genetic variations on the pharmacokinetics and pharmacodynamics of commonly used antidiabetic drugs, including metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, and SGLT2 inhibitors. Materials and methods: A systematic review of existing literature was carried out, concentrating on studies exploring personalized medicine in T2D through pharmacogenomics. The literature search encompassed databases such as Medline, Scopus, Web of Science (WOS), and PubMed. Key insights regarding the role of pharmacogenomics in managing T2D were compiled and analyzed. Results and conclusions: The review highlights how genetic polymorphisms in drug transporters, metabolizing enzymes, and drug targets correlate with variations in drug response and tolerance. We advocate for preemptive genotyping and integration of genetic data into clinical decision-making, which could revolutionize patient care in T2D. The future of diabetes treatment lies in harnessing pharmacogenomic insights to tailor therapeutic regimens, thereby transitioning from a one-size-fits-all approach to a more nuanced, individualized treatment strategy. With advancements in genomic technologies and a reduction in genotyping costs, the implementation of genetic testing in routine clinical practice is becoming increasingly viable, signaling a new era in the personalized management of T2D.